drugset / Trial / NCT05263388

A Trial to Compare the Ovarian Response of REKOVELLE and GONAL-F in Conventional Dosing in Women Undergoing Controlled Ovarian Stimulation

NCT05263388

Phase 3 Completed 302 enrolled Ferring Pharmaceuticals
RandomizedParallel-groupSingle-blindTreatment

Summary

Hormone preparations like REKOVELLE and GONAL-F are used to make the body produce multiple egg sacs, allowing more eggs to be collected from women undergoing infertility treatment. The main purpose of this trial is to see how many eggs are produced with a starting dose of 15 µg REKOVELLE compared to a starting dose of 225 IU GONAL-F. This research is intended to provide more knowledge about REKOVELLE, including the doses given in the trial.

Timeline

Start
2022-07-15
Primary completion
2024-04-16
Completion
2024-04-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Follitropin delta Protein / enzyme biologic 15 ug Subcutaneous
Subject Gonal-f Protein / enzyme biologic 225 iu Subcutaneous

Indications